biosimilars

News

Remaining Challenges, Potential Solutions for the Regulatory Evaluation of Biosimilars

12/16/2020

A recent article outlines challenges that remain regarding the regulatory evaluation of biosimilars and offers potential solutions for the future.

A recent article outlines...

12/16/2020

Journal of Clinical Pathways

News

Policy Review on Improving Oncology Biosimilar Launches

12/11/2020

A recent policy review identifies factors that prevent the effective launch of oncology biosimilars.

A recent policy review...

12/11/2020

Journal of Clinical Pathways

News

ACP Recommendations for Improving Market Competition

09/21/2020

A position paper released by the American College of Physicians made concrete policy reform suggestions for prescription drug competition, calling for a realignment of incentives and rewards for true innovation.

A position paper released by the...

09/21/2020

Journal of Clinical Pathways

News

Oncologist Perception of Efficacy, Safety, and Willingness to Prescribe Biosimilars

06/26/2020

Researchers from CVS Health assessed the expected biosimilar prescribing behaviors of practicing oncologists for originator products bevacizumab, trastuzumab, rituximab, and pegfilgrastim. Biosimilars are a...

...

06/26/2020

Journal of Clinical Pathways

News

Cost Savings With Biosimilar in Prophylaxis of Chemo-Induced Febrile Neutropenia

06/19/2020

Researchers from the University of Arizona Cancer Center conducted simulation modeling of cost savings from conversion of pegfilgrastim to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced...

...

06/19/2020

Journal of Clinical Pathways

Research Reports

Implications of Manufacturer Contracting: A Quantitative Model to Assess Biosimilar Market Feasibility

10/15/2018

Michael Kuehn, RPh

Jay Galli

Abstract: Eight years have passed since Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) of 2010. Since then, 12 biosimilars have received approval from the Food and Drug Administration,...

...

10/15/2018

Journal of Clinical Pathways

Research Reports

Community Oncologists` Perception and Acceptance of Biosimilars in Oncology

09/13/2018

Chadi Nabhan, MD, MBA, FACP

Yolaine Jeune-Smith, PhD

Amy Valley, PharmD

Bruce A Feinberg, DO

Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...

...

09/13/2018

Journal of Clinical Pathways